Press Releases

  The decision to discontinue enrollment into the study was based on the recommendation from the independent Data Safety Monitoring Board (DSMB) following a planned interim futility analysis conducted once 57 deaths (50% of the target number of...

Novartis announced today that the US FDA has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. ...

Amgen and Advaxis, Inc announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or...

Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testingPotential combination of WO-12 with Pfizer’s oncology pipeline could enhance therapeutic benefit in patients. Pfizer Inc and Western Oncolytics announced that they have entered into...

Thailand, 2nd largest economy in South East Asia, promotes foreign investment with new S curve structure towards innovative, digital and research based economy, leading the country to the new dimension of laboratory, biotechnology and life science investment in ASEAN....

 Janssen Biotech, Inc.  announced it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC). The Phase 2...

Amgen announced that the U.S. FDA has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 mg...